Careers  |  Sign In  |  Register  |   Twitter

MannKind Corp’s Inhaled Insulin Receives Strong Recommendation for Approval

Reuters reports that “MannKind Corp‘s shares doubled on Wednesday, after an advisory committee to the U.S. health regulator recommended approval of the drug developer’s inhaled insulin treatment.” The drug, Afrezza, received a 13-1 vote to recommend its approval for patients with type 1 diabetes, and the advisory panel “unanimously backed it for those with type 2, but said longer-term studies would be required to gauge the risk of lung cancer and other potential side-effects.”

Read the article published by Reuters.